TSC2 and lymphangioleiomyomatosis: The idea of a combination treatment is not new in LAM, as in 2015, Alayev and colleagues reported promising results from combining Rapamycin with resveratrol, an autophagy inhibitor, in a Tsc2-null xenograft tumor model.